Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases By webadmin@biolojic.com|2024-04-29T13:08:21+00:00April 29, 2024|Uncategorized|0 Comments Read More